All News

Abstracts from the American Epilepsy Society annual meeting show that telemedicine is capable of meeting the needs of patients with epilepsy, and that the patient portal accessibility for patients experiencing high social vulnerability index needs further research.

Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.

Authors of the observational cohort study developed and validated novel sex-informed prognostic and genomic scoring systems for patients with myelodysplastic syndrome (MDS).

Patients with Parkinson disease who adhered to Mediterranean (MEDI) and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets were associated with fewer patient-reported symptoms over time, in which the MIND diet showed greater reductions in symptom severity compared with MEDI.

About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

Amgen will buy Horizon Therapeutics for $27.8 billion as the largest health care merger of 2022; high levels of 3 respiratory illness incite reassessment of domestic indoor mask guidelines; Juul Labs is reported to pay $1.7 billion over 500 settlements that claim that e-cigarette addiction level is higher than advertised.

The report is the first recorded case of acute respiratory distress syndrome (ARDS) that required venovenous extracorporeal membrane oxygenation and was complicated by spontaneous spleen rupture.

Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.

Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden bleeding events.

Federico Stella, MD, University of Milan, explains why it was important to challenge the idea that the low-microbial protective diet is more beneficial than a nonrestrictive diet in patients with neutropenia.

Results from a phase 3 study of patients with acute myeloid leukemia (AML) are being presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.

Building equitable clinical trials means being thoughtful about trial design and criteria, said Matthew J. Maurer, DSc, statistician at Mayo Clinic, director of the statistics and informatics core of the Lymphoma Epidemiology of Outcomes (LEO) cohort.

Aerobic capacity and cardiovascular risk both improve when people with systemic lupus erythematosus (SLE) exercise regularly, according to a new systematic review.

Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.

The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant therapy for early-stage, high-risk breast cancer, and new data were presented yesterday at the San Antonio Breast Cancer Symposium.

Babytam is the 5-mg daily dose of tamoxifen being studied in the ongoing TAM-01 study, which is investigating incidence of invasive breast cancer or ductal carcinoma in situ among high-risk women who have received the treatment regimen for 3 years.

Infertility and mental health have a complex relationship, with the impact of mental distress in evaluating for infertility and fertility treatments being quite significant.

Mental and physical health aspects of quality of life (QOL) improved after sutimlimab treatment in patients with cold agglutin disease (CAD) during a phase 3 trial.

Patient-reported outcomes (PROs) within breast cancer settings can be instrumental in helping patients feel heard and improving their overall quality of care, said Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS, chief of breast surgery at Penn Medicine.

A retrospective cohort study found that rapid thinning of the ganglion cell complex was associated with central visual field decline.

Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.

A cohort study found that chronic kidney disease (CKD) was associated with the development of abdominal aortic aneurysm, with risk increasing as CKD stage advanced.

Abstracts from the American Epilepsy Society (AES) display potential benefits of cannabidiol (CBD) on pediatric patients with epilepsy in tertiary care centers and highlight areas where further research is needed.

Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.